Virtual screening of biogenic amine-binding G-protein coupled receptors: Comparative evaluation of protein- and ligand-based virtual screening protocols

Journal of Medicinal Chemistry

Volumn 48, Issue 17, 2005, Pages 5448-5465

  Evers, Andreas ^a   Hessler, Gerhard ^a   Matter, Hans ^a   Klabunde, Thomas ^a  

^a SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 1 [2 [4 (6 FLUORO 1,2 BENZISOXAZOL 3 YL) 1 PIPERIDYL]ETHYL] 3 PHENYL 2 IMIDAZOLINONE; 2 [2 (4 HYDROXYPHENYL)ETHYLAMINOMETHYL]TETRALONE; 2 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 4,4 DIMETHYL 1,3(2H,4H) ISOQUINOLINEDIONE; 5 CHLORO N [2 (2 CYCLOPROPYLMETHOXYPHENOXY)ETHYL] ALPHA,ALPHA DIMETHYL 1H INDOLE 3 ETHANAMINE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; BIOGENIC AMINE; CHLORPROMAZINE; CLOZAPINE; CYCLAZOCINE; CYPROHEPTADINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOXAZOSIN; ETICLOPRIDE; FLUPENTIXOL; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; ILOPERIDONE; KETANSERIN; LIGAND; MIANSERIN; PROTEIN; RISPERIDONE; RITANSERIN; RMI 60947; SEROTONIN 2 ANTAGONIST; SPIPERONE; TAMSULOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WB 4104;

ARTICLE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EVALUATION; INTERMETHOD COMPARISON; MODEL; PHARMACOPHORE; PROTEIN BINDING; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; STRUCTURE ACTIVITY RELATION;

BINDING SITES; BIOGENIC AMINES; DATABASES, FACTUAL; LEAST-SQUARES ANALYSIS; LIGANDS; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTOR, MUSCARINIC M1; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE D2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 23944454816     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050090o     Document Type: Article

References (88)

1. Bleicher, K. H.; Bohm, H. J.; Muller, K.; Alanine, A. I. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discovery 2003, 2, 369-378.
2. Oprea, T. I.; Matter, H. Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. 2004, 8, 349-358.
3. Sadowski, J.; Kubinyi, H. A scoring scheme for discriminating between drugs and nondrugs. J. Med. Chem. 1998, 41, 3325-3329.
4. Roy, K. Topological descriptors in drug design and modeling studies. Mol. Diversity 2004, 8, 321-323.
5. Lengauer, T.; Lemmen, C.; Rarey, M.; Zimmermann, M. Novel technologies for virtual screening. Drug Discovery Today 2004, 9, 27-34.
6. Rarey, M.; Dixon, J. S. Feature trees: a new molecular similarity measure based on tree matching. J. Comput.-Aided Mol. Des. 1998, 12, 471-490.
7. Roche, O.; Trube, G.; Zuegge, J.; Pflimlin, P.; Alanine, A.; Schneider, G. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. ChemBioChem 2002, 3, 455-459.
8. Roche, O.; Schneider, P.; Zuegge, J.; Guba, W.; Kansy, M.; Alanine, A.; Bleicher, K.; Danel, F.; Gutknecht, E. M.; Rogers-Evans, M.; Neidhart, W.; Stalder, H.; Dillon, M.; Sjogren, E.; Fotouhi, N.; Gillespie, P.; Goodnow, R.; Harris, W.; Jones, P.; Taniguchi, M.; Tsujii, S.; von der Saal, W.; Zimmermann, G.; Schneider, G. Development of a virtual screening method for identification of "frequent hitters" in compound libraries. J. Med. Chem. 2002, 45, 137-142.
9. Lemmen, C.; Lengauer, T.; Klebe, G. FLEXS: a method for fast flexible ligand superposition. J. Med. Chem. 1998, 41, 4502-4520.
10. Guner, O.; Clement, O.; Kurogi, Y. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst: recent advances. Curr. Med. Chem. 2004, 11, 2991-3005.
11. Halperin, I.; Ma, B.; Wolfson, H.; Nussinov, R. Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins 2002, 47, 409-443.
12. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discovery. 2004, 3, 935-949.
13. Sotriffer, C.; Klebe, G. Identification and mapping of small-molecule binding sites in proteins: computational tools for structure-based drug design. Farmaco 2002, 57, 243-251.
14. Alvarez, J. C. High-throughput docking as a source of novel drug leads. Curr. Opin. Chem. Biol. 2004, 8, 365-370.
15. Brenk, R.; Naerum, L.; Gradler, U.; Gerber, H. D.; Garcia, G. A.; Reuter, K.; Stubbs, M. T.; Klebe, G. Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis. J. Med. Chem. 2003, 46, 1133-1143.
16. Gruneberg, S.; Stubbs, M. T.; Klebe, G. Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. J. Med. Chem. 2002, 45, 3588-3602.
17. Kraemer, O.; Hazemann, I.; Podjarny, A. D.; Klebe, G. Virtual screening for inhibitors of human aldose reductase. Proteins 2004, 55, 814-823.
18. Powers, R. A.; Morandi, F.; Shoichet, B. K. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure (Cambridge, MA, U. S.) 2002, 10, 1013-1023.
19. Soelaiman, S.; Wei, B. Q.; Bergson, P.; Lee, Y. S.; Shen, Y.; Mrksich, M.; Shoichet, B. K.; Tang, W. J. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 2003, 278, 25990-25997.
20. Liu, H.; Li, Y.; Song, M.; Tan, X.; Cheng, F.; Zheng, S.; Shen, J.; Luo, X.; Ji, R.; Yue, J.; Hu, G.; Jiang, H.; Chen, K. Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing. Chem. Biol. 2003, 10, 1103-1113.
21. Vangrevelinghe, E.; Zimmermann, K.; Schoepfer, J.; Portmann, R.; Fabbro, D.; Furet, P. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J. Med. Chem. 2003, 46, 2656-2662.
22. Klabunde, T.; Hessler, G. Drug design strategies for targeting G-protein-coupled receptors. ChemBioChem 2002, 3, 928-944.
23. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Fournier, A.; Klabunde, T. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
24. Marriott, D. P.; Dougall, I. G.; Meghani, P.; Liu, Y. J.; Flower, D. R. Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists. J. Med. Chem. 1999, 42, 3210-3216.
25. Kalani, M. Y.; Vaidehi, N.; Hall, S. E.; Trabanino, R. J.; Freddolino, P. L.; Kalani, M. A.; Floriano, W. B.; Kam, V. W.; Goddard, W. A., III The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 3815-3820.
26. Freddolino, P. L.; Kalani, M. Y.; Vaidehi, N.; Floriano, W. B.; Hall, S. E.; Trabanino, R. J.; Kam, V. W.; Goddard, W. A., III Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 2736-2741.
27. Vaidehi, N.; Floriano, W. B.; Trabanino, R.; Hall, S. E.; Freddolino, P.; Choi, E. J.; Zamanakos, G.; Goddard, W. A., III Prediction of structure and function of G protein-coupled receptors. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 12622-12627.
28. Evers, A.; Klebe, G. Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J. Med. Chem. 2004, 47, 5381-5392.
29. Costanzi, S.; Mamedova, L.; Gao, Z. G.; Jacobson, K. A. Architecture of P2Y nucleotide receptors: structural comparison based on sequence analysis, mutagenesis, and homology modeling. J. Med. Chem. 2004, 47, 5393-5404.
30. Broer, B. M.; Gurrath, M.; Holtje, H. D. Molecular modelling studies on the ORL1-receptor and ORL1-agonists. J. Comput.-Aided Mol. Des. 2003, 17, 739-754.
31. Furse, K. E.; Lybrand, T. P. Three-dimensional models for beta-adrenergic receptor complexes with agonists and antagonists. J. Med. Chem. 2003, 46, 4450-4462.
32. Johren, K.; Holtje, H. D. A model of the human M2 muscarinic acetylcholine receptor. J. Comput.-Aided Mol. Des. 2002, 16, 795-801.
33. Lavecchia, A.; Greco, G.; Novellino, E.; Vittorio, F.; Ronsisvalle, G. Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. J. Med. Chem. 2000, 43, 2124-2134.
34. Pedretti, A.; Elena, S. M.; Villa, L.; Vistoli, G. Binding site analysis of full-length alpha1α adrenergic receptor using homology modeling and molecular docking. Biochem. Biophys. Res. Commun. 2004, 319, 493-500.
35. Salo, O. M.; Lahtela-Kakkonen, M.; Gynther, J.; Jarvinen, T.; Poso, A. Development of a 3D model for the human cannabinoid CB1 receptor. J. Med. Chem. 2004, 47, 3048-3057.
36. Shim, J. Y.; Welsh, W. J.; Hewlett, A. C. Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. Biopolymers 2003, 71, 169-189.
37. Hardin, C.; Pogorelov, T. V.; Luthey-Schulten, Z. Ab initio protein structure prediction. Curr. Opin. Struct. Biol. 2002, 12, 176-181.
38. Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of G-protein coupled receptors suitable targets? Proteins 2003, 50, 5-25.
39. Evers, A.; Klabunde, T. Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J. Med. Chem. 2005, 48, 1088-1097.
40. Varady, J.; Wu, X.; Fang, X.; Min, J.; Hu, Z.; Levant, B.; Wang, S. Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. J. Med. Chem. 2003, 46, 4377-4392.
41. Dixon, J. S. Evaluation of the CASP2 docking section. Proteins 1997, Suppl. 1, 198-204.
42. Ferrara, P.; Gohlke, H.; Price, D. J.; Klebe, G.; Brooks, C. L., III Assessing scoring functions for protein-ligand interactions. J. Med. Chem. 2004, 47, 3032-3047.
43. Wang, R.; Lu, Y.; Wang, S. Comparative evaluation of 11 scoring functions for molecular docking. J. Med. Chem. 2003, 46, 2287-2303.
44. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
45. Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
46. Verdonk, M. L.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Taylor, R. D. Improved protein-ligand docking using GOLD. Proteins 2003, 52, 609-623.
47. Hindle, S. A.; Rarey, M.; Buning, C.; Lengaue, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 2002, 16, 129-149.
48. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol. 1996, 261, 470-489.
49. Hessler, G.; Zimmermann, M.; Matter, H.; Evers, A.; Naumann, T.; Lengauer, T.; Rarey, M. Multiple-ligand-based virtual screening: Methods and Applications of the m-tree approach. J. Med. Chem., in press.
50. Schneider, G.; Clement-Chomienne, O.; Hilfiger, L.; Schneider, P.; Kirsch, S.; Bohm, H. J.; Neidhart, W. Virtual screening for bioactive molecules by evolutionary de novo design special thanks to Neil R. Taylor for his help in preparation of the manuscript. Angew. Chem., Int. Ed. 2000, 39, 4130-4133.
51. Schneider, G.; Neidhart, W.; Giller, T.; Schmid, G. "Scaffold- hopping" by topological pharmacophore search: a contribution to virtual screening. Angew. Chem., Int. Ed. 1999, 38, 2894-2896.
52. Grethe, G.; Moock, T. E. Similarity searching in REACCS. A new tool for the synthetic chemist. J. Chem. Inf. Comput. Sci. 1990, 30, 511-520.
53. Jorgensen, W. L.; Duffy, E. M. Prediction of drug solubility from structure. Adv. Drug Delivery Rev. 2002, 54, 355-366.
54. Jorgensen, W. L.; Duffy, E. M. Prediction of drug solubility from Monte Carlo simulations. Bioorg. Med. Chem. Lett. 2000, 10, 1155-1158.
55. Pirard, B.; Pickett, S. D. Classification of kinase inhibitors using BCUT descriptors. J. Chem. Inf. Comput. Sci. 2000, 40, 1431-1440.
56. Matter, H. Selecting optimally diverse compounds from structure databases: a validation study of two-dimensional and three-dimensional molecular descriptors. J. Med. Chem. 1997, 40, 1219-1229.
57. Matter, H. Computational approaches towards the quantification of molecular diversity and design of compound libraries. EXS 2003, 125-156.
58. Cramer, R. D.; Poss, M. A.; Hermsmeier, M. A.; Caulfield, T. J.; Kowala, M. C.; Valentine, M. T. Prospective identification of biologically active structures by topomer shape similarity searching. J. Med. Chem. 1999, 42, 3919-3933.
59. Hert, J.; Willett, P.; Wilton, D. J.; Acklin, P.; Azzaoui, K.; Jacoby, E.; Schuffenhauer, A. Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. Org. Biomol. Chem. 2004, 2, 3256-3266.
60. Hert, J.; Willett, P.; Wilton, D. J.; Acklin, P.; Azzaoui, K.; Jacoby, E.; Schuffenhauer, A. Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures. J. Chem. Inf. Comput. Sci. 2004, 44, 1177-1185.
61. Schuffenhauer, A.; Gillet, V. J.; Willett, P. Similarity searching in files of three-dimensional chemical structures: analysis of the BIOSTER database using two-dimensional fingerprints and molecular field descriptors. J. Chem. Inf. Comput. Sci. 2000, 40, 295-307.
62. Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudiniere, R. F. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J. Med. Chem. 1999, 42, 3251-3264.
63. Sun, H. Prediction of chemical carcinogenicity from molecular structure. J. Chem. Inf. Comput. Sci. 2004, 44, 1506-1514.
64. Shen, M.; Beguin, C.; Golbraikh, A.; Stables, J. P.; Kohn, H.; Tropsha, A. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds. J. Med. Chem. 2004, 47, 2356-2364.
65. Baurin, N.; Mozziconacci, J. C.; Arnoult, E.; Chavatte, P.; Marot, C.; Morin-Allory, L. 2D QSAR consensus prediction for high-throughput virtual screening. An application to COX-2 inhibition modeling and screening of the NCI database. J. Chem. Inf. Comput. Sci. 2004, 44, 276-285.
66. Sutherland, J. J.; O'Brien, L. A.; Weaver, D. F. A comparison of methods for modeling quantitative structure-activity relationships. J. Med. Chem. 2004, 47, 5541-5554.
67. Roche, O.; Trube, G.; Zuegge, J.; Pflimlin, P.; Alanine, A.; Schneider, G. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. ChemBioChem 2002, 3, 455-459.
68. Shi, L.; Javitch, J. A. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 2002, 42, 437-467.
69. Hamaguchi, N.; True, T. A.; Saussy, D. L., Jr.; Jeffs, P. W. Phenylalanine in the second membrane-spanning domain of alpha 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry 1996, 35, 14312-14317.
70. Hamaguchi, N.; True, T. A.; Goetz, A. S.; Stouffer, M. J.; Lybrand, T. P.; Jeffs, P. W. Alpha 1-adrenergic receptor subtype determinants for 4-piperidyl oxazole antagonists. Biochemistry 1998, 37, 5730-5737.
71. Klabunde, T.; Evers, A. GPCR anti-target modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side-effects. ChemBioChem 2005, 6, 876-889.
72. Sheridan, R. P.; Feuston, B. P.; Maiorov, V. N.; Kearsley, S. K. Similarity to molecules in the training set is a good discriminator for prediction accuracy in QSAR. J. Chem. Inf. Comput. Sci. 2004, 44, 1912-1928.
73. Schnecke, V.; Swanson, C. A.; Getzoff, E. D.; Tainer, J. A.; Kuhn, L. A. Screening a peptidyl database for potential ligands to proteins with side-chain flexibility. Proteins 1998, 33, 74-87.
74. Schnecke, V.; Kuhn, L. A. Database screening for HIV protease ligands: the influence of binding-site conformation and representation on ligand selectivity. Proc. Int. Conf. Intell. Syst. Mol. Biol. 7th 1999, 242-251.
75. Ewing, T. J.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 2001, 15, 411-428.
76. McGovern, S. L.; Shoichet, B. K. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J. Med. Chem. 2003, 46, 2895-2907.
77. Gouldson, P. R.; Kidley, N. J.; Bywater, R. P.; Psaroudakis, G.; Brooks, H. D.; Diaz, C.; Shire, D.; Reynolds, C. A. Toward the active conformations of rhodopsin and the beta2-adrenergic receptor. Proteins 2004, 56, 67-84.
78. Bemis, G. W.; Murcko, M. A. The properties of known drugs. 1. Molecular frameworks. J. Med. Chem. 1996, 39, 2887-2893.
79. Evers, A.; Gohlke, H.; Klebe, G. Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. J. Mol. Biol. 2003, 334, 327-345.
80. Good, A. C.; Cheney, D. L.; Sitkoff, D. F.; Tokarski, J. S.; Stouch, T. R.; Bassolino, D. A.; Krystek, S. R.; Li, Y.; Mason, J. S.; Perkins, T. D. Analysis and optimization of structure-based virtual screening protocols. 2. Examination of docked ligand orientation sampling methodology: mapping a pharmacophore for success. J. Mol. Graphics Modell. 2003, 22, 31-40.
81. Fradera, X.; Knegtel, R. M.; Mestres, J. Similarity-driven flexible ligand docking. Proteins 2000, 40, 623-636.
82. Kuntz, I. D.; Blaney, J. M.; Oatley, S. J.; Langridge, R.; Ferrin, T. E. A geometric approach to macromolecule-ligand interactions. J. Mol. Biol. 1982, 161, 269-288.
83. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
84. Muegge, I.; Martin, Y. C. A general and fast scoring function for protein-ligand interactions: a simplified potential approach. J. Med. Chem. 1999, 42, 791-804.
85. Gohlke, H.; Hendlich, M.; Klebe, G. Knowledge-based scoring function to predict protein-ligand interactions. J. Mol. Biol. 2000, 295, 337-356.
86. Kehne, J. H.; Baron, B. M.; Carr, A. A.; Chaney, S. F.; Elands, J.; Feldman, D. J.; Frank, R. A.; van Giersbergen, P. L.; McCloskey, T. C.; Johnson, M. P.; McCarty, D. R.; Poirot, M.; Senyah, Y.; Siegel, B. W.; Widmaier, C. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 1996, 277, 968-981.
87. Corbett, R.; Hartman, H.; Kerman, L. L.; Woods, A. T.; Strupczewski, J. T.; Helsley, G. C.; Conway, P. C.; Dunn, R. W. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol., Biochem. Behav. 1993, 45, 9-17.
88. Mitsuya, M.; Kobayashi, K.; Kawakami, K.; Satoh, A.; Ogino, Y.; Kakikawa, T.; Ohtake, N.; Kimura, T.; Hirose, H.; Sato, A.; Numazawa, T.; Hasegawa, T.; Noguchi, K.; Mase, T. A potent, long-acting, orally active (2R)-2-[(1R)-3,3- difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: novel muscarinic M(3) receptor antagonist with high selectivity for M(3) over M(2) receptors. J. Med. Chem. 2000, 43, 5017-5029.